1-2 of 2
Ina Rhee
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Tae Won Kim, Howard A. Burris, III, Maria J. de Miguel Luken, Michael J. Pishvaian, Yung-Jue Bang, Michael Gordon, Ahmad Awada, D. Ross Camidge, F. Stephen Hodi, Grant A. McArthur, Wilson H. Miller, Jr, Andres Cervantes, Laura Q. Chow, Alexander M. Lesokhin, Annemie Rutten, Mario Sznol, Deepali Rishipathak, Shang-Chiung Chen, Eric Stefanich, Tony Pourmohamad, Maria Anderson, Jeong Kim, Mahrukh Huseni, Ina Rhee, Lillian L. Siu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3452–3463.
https://doi.org/10.1158/1078-0432.CCR-21-4020
Published: 15 August 2022
View article titled, First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Open the PDF for First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Kyung Hae Jung, Patricia LoRusso, Howard Burris, Michael Gordon, Yung-Jue Bang, Matthew D. Hellmann, Andrés Cervantes, Maria Ochoa de Olza, Aurelien Marabelle, F. Stephen Hodi, Myung-Ju Ahn, Leisha A. Emens, Fabrice Barlesi, Omid Hamid, Emiliano Calvo, David McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Tsuhako, Kari Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (11): 3220–3228.
https://doi.org/10.1158/1078-0432.CCR-18-2740
Published: 03 June 2019
View article titled, Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Open the PDF for Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors in another window